俄罗斯医疗器械注册新规再度延期，境外厂商授权代表过渡期延期！ - Wiselink Group-A More Controllable, Stable, and Future-Oriented Material Direction

Home > News Center > Russia Postpones New Medical Device Registration Rules Again – Extended Transition Period for Foreign Manufacturers’ Authorized Representatives

Russia Postpones New Medical Device Registration Rules Again – Extended Transition Period for Foreign Manufacturers’ Authorized Representatives

Time：2026-06-18 14:38:26

On June 2, 2026, Russian pharmaceutical industry media Pharmvestnik released the latest regulatory update: the Ministry of Health of the Russian Federation formally proposed to postpone the enforcement of compliance rules governing local authorized representatives of foreign medical device manufacturers by one year. This adjustment affects all overseas medical device enterprises with market layouts in Russia, granting the industry ample time to complete compliance rectification.

原

文

链

接

https://pharmvestnik.ru/content/news/normu-ob-otmene-registracii-medizdelii-bez-upolnomochennogo-predstavitelya-hotyat-otlojit-na-god.html

一、Policy Background

To fully grasp the impact of this postponement, it is critical to clarify the legal status of authorized representatives stipulated in Government Decree No. 1684 — the core policy behind Russia’s tightened medical device supervision in recent years.

The Federal Service for Surveillance in Healthcare (Roszdravnadzor, abbreviated RZN) oversees the full lifecycle management of medical devices in Russia, covering all imported device registration, post-market surveillance, adverse event reporting and market sampling inspections.

For foreign manufacturers, a Russian local authorized representative (RUS REP) is far more than a commercial agent; they are a statutory liable legal entity. As the sole official liaison between overseas manufacturers and Russian regulators, the local authorized representative manages full-cycle compliance work including registration filings and dossier amendments, and submits mandatory annual notifications. They bear joint and several legal liability for product labeling compliance, electronic traceability system operation, adverse event reporting and post-market product recalls. Regulators may hold the authorized representative directly accountable for violations, and the representative’s legal qualification and operational stability determine whether foreign products can remain legally marketed in Russia.

Russia introduced the mandatory local authorized representative system for two primary objectives:

Align its domestic regulatory framework with the medical device rules of the Eurasian Economic Union (EAEU) and the European Union to build a full-chain oversight system;
Strengthen safety control over imported medical devices and enforce full product traceability accountability.

二、Core Policy Revisions

This amendment targets the Rules for State Registration of Medical Devices (Government Decree No. 1684 of the Russian Federation, issued November 30, 2024), the primary governing regulation for medical device registration in Russia. The decree officially entered into force on March 1, 2025, launching a new registry-based management model for all medical device registration certificates.

（一）Original Mandatory Regulatory Red Line

The regulation sets an absolute compliance threshold: foreign medical device manufacturers without a legally established authorized representative resident in Russia are ineligible to apply for state registration, and existing registered products will face automatic invalidation of their market access credentials. All enterprises holding active registration certificates must complete updates to their authorized representative information within the prescribed deadline; failure to comply will result in revocation of all registration qualifications.

（二）Proposed Dual One-Year Extensions in the Draft Amendment

The Ministry of Health of Russia has drafted an amendment introducing two synchronized one-year delays:Postpone the effective date of the clause barring medical device registration for foreign manufacturers without a Russian authorized representative by one full calendar year;Extend the transition period for manufacturers to update and file authorized representative information by one year.The unified new compliance deadline is set as September 1, 2027.

（三）Current Policy Progress

The draft amendment has entered the public consultation phase open to all market participants. Public comments and feedback will be accepted until June 16, 2026. Upon completion of the consultation window, the draft will advance to subsequent official approval procedures, with an extremely high probability of formal enactment and enforcement.

三、Official Rationale for the One-Year Postponement

In the explanatory memorandum attached to the draft amendment, Russian authorities outlined the core practical concerns driving the delay:

Foreign medical device manufacturers currently require far more time than anticipated to prepare full supporting documentation for authorized representative appointments, including notarized legal papers and power-of-attorney agreements, plus official filing materials. Strict enforcement under the original timeline would leave thousands of overseas manufacturers unable to complete the setup of a compliant local authorized representative before the deadline.

This scenario would trigger severe systemic risks:

Mass cancellation of imported medical device registrations, blocking customs clearance and domestic cross-border circulation;

Severe supply shortages of clinically essential medical devices across Russia’s public healthcare network;

Critical gaps in safety oversight, adverse incident handling and product traceability due to the absence of a local statutory liable party, ultimately endangering patient safety and disrupting the normal order of Russia’s medical market.

Based on comprehensive risk prevention and control assessments, the Russian Ministry of Health resolved to extend the transition period once again.

四、Industry-Wide Impacts

This policy adjustment applies to all Chinese medical device exporters to Russia, foreign trade service providers and local Russian distributors, delivering differentiated benefits to each stakeholder group:

（一）Foreign Medical Device Manufacturers (Including Chinese Enterprises Expanding Overseas)

This group stands to gain the most from the extended grace period. Previously, many manufacturers faced overlapping administrative burdens including authorized representative screening, partnership contract negotiations, Russian legal document translation, overseas notarization and official system data updates. Small and medium-sized manufacturers in particular encountered insurmountable compliance bottlenecks due to the lengthy, complex procedural chain. The additional one-year buffer allows enterprises to systematically organize all qualification documents, formalize agency cooperation agreements and complete full official filings, avoiding forced product delistings and the loss of years of accumulated market investment caused by expired compliance deadlines.

（二）Russia’s Domestic Medical Device Market

The postponement guarantees stable supply of imported medical devices in the short term. Russia operates an extensive public healthcare system, where imported high-value consumables, diagnostic equipment and implantable devices account for a dominant share of clinical usage. The delayed implementation of the new regulatory rules eliminates the risk of nationwide medical device shortages and ensures the normal daily operation of all medical institutions. Meanwhile, the phased rollout of the new system enables regulatory authorities to gradually adapt to the revised framework without being overwhelmed by sudden surges in administrative workload.

（三）Local Russian Authorized Representatives & Compliance Service Institutions

The extended transition period lengthens commercial operation cycles for all compliance service providers, granting additional time to onboard global overseas clients and refine standardized end-to-end service systems, accelerating the formalization and maturity of Russia’s medical device compliance service industry.

五、Practical Operational Guidance for Export Enterprises

While the policy delivers a one-year compliance grace period, the mandatory local authorized representative requirement remains an irreversible long-term regulatory trend and will not be abolished due to the delay. Combining established Russian regulatory rules and real-world industry practice, we have compiled core action recommendations for manufacturers expanding into the Russian market:

Finalize a fully compliant local authorized representative as soon as possible;

Conduct a full audit and sorting of registration information for all existing registered products;

Align new product registration workflows with the revised regulatory requirements in advance;

Continuously track the final official enactment text of the amended policy;

Establish a comprehensive end-to-end enterprise compliance management system.

六、Conclusion

From a long-term regulatory development perspective, Russia’s medical device market continues to raise market access thresholds and strengthen full lifecycle supervision, gradually converging with globally recognized high-standard regulatory frameworks. The mandatory local authorized representative system represents an irreversible regulatory direction for the country. The one-year transition extension is a flexible, pragmatic adjustment tailored to real industry operational conditions, designed to facilitate a smooth compliance transition for global manufacturers rather than a relaxation of regulatory oversight standards.

Previous：FDA Breakthrough Devices Program: The Golden Fast Track for Innovative Medical Devices Entering the U.S. Market Next：What Value Does FDA 510(k) Hold? Full In-Depth Breakdown of Clearance Letters

Fill Form

Whether you need more information or wish to cooperate with us, we will guide you through every step of the regulatory process. Subscribe to our newsletter for the latest global regulatory updates.